Literature DB >> 10768295

Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture.

M J McLean1, A A Bukhari, A W Wamil.   

Abstract

PURPOSE: The effects of topiramate (TPM) on sodium-dependent action potentials were studied by using cultured mouse spinal cord neurons.
METHODS: The ability of TPM to limit (block) depolarization-induced spontaneous repetitive firing (SRF) was determined and compared with corresponding effects of phenytoin (PHT) and lamotrigine (LTG) in cultured mouse spinal neurons.
RESULTS: Topiramate at concentrations of > or =3 microM caused a voltage-sensitive and time-dependent limitation of SRF that was associated with a decrease in the velocity of the upstroke of the action potential. At high concentrations (30-600 microM), TPM rapidly blocked SRF in about one third of the neurons tested and did not affect SRF in about one third. In some neurons, TPM caused an intermittent limitation (sputtering) of SRF (approximately 30% of the neurons) or blocked SRF only after a delay of several seconds (approximately 10%). This complex pattern of effects is distinctly different from that of PHT and LTG, in which the effect was always a rapid limitation or complete blockade of SRF. Another difference between TPM and the other anticonvulsants (AEDs) is that the effects of TPM were more dependent on the length of time the neurons were exposed to the compound and the intensity or duration of neuronal activity.
CONCLUSIONS: The results of this study do not support the concept that Na+ channel blockade is the primary mechanism responsible for the anticonvulsant activity of TPM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768295

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  20 in total

Review 1.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Phosphorylation of sodium channels mediated by protein kinase-C modulates inhibition by topiramate of tetrodotoxin-sensitive transient sodium current.

Authors:  G Curia; P Aracri; E Colombo; P Scalmani; M Mantegazza; G Avanzini; S Franceschetti
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

3.  Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation.

Authors:  M Inghilleri; F Gilio; A Conte; V Frasca; C Marini Bettolo; E Iacovelli; B Gregori; M Prencipe; A Berardelli
Journal:  Exp Brain Res       Date:  2006-08-05       Impact factor: 1.972

4.  Seizure recurrence and remission after switching antiepileptic drugs.

Authors:  Sophia Pan Wang; Scott Mintzer; Christopher T Skidmore; Tingting Zhan; Erika Stuckert; Maromi Nei; Michael R Sperling
Journal:  Epilepsia       Date:  2012-08-29       Impact factor: 5.864

5.  Efficacy of Topiramate as an add-on drug in seizures in Indian children--an observational study.

Authors:  Priya Sreenivasan; P A Mohammed Kunju
Journal:  Indian J Pediatr       Date:  2011-03-05       Impact factor: 1.967

6.  Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3- exchange.

Authors:  Tobias Leniger; Jan Thöne; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 7.  Molecular mechanisms of antiseizure drug activity at GABAA receptors.

Authors:  L John Greenfield
Journal:  Seizure       Date:  2013-05-14       Impact factor: 3.184

Review 8.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12

Review 9.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

10.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.